1. Home
  2. LGVN vs MYNZ Comparison

LGVN vs MYNZ Comparison

Compare LGVN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGVN
  • MYNZ
  • Stock Information
  • Founded
  • LGVN 2014
  • MYNZ 2021
  • Country
  • LGVN United States
  • MYNZ Germany
  • Employees
  • LGVN N/A
  • MYNZ N/A
  • Industry
  • LGVN Medicinal Chemicals and Botanical Products
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGVN Health Care
  • MYNZ Health Care
  • Exchange
  • LGVN Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • LGVN 31.2M
  • MYNZ 9.8M
  • IPO Year
  • LGVN 2021
  • MYNZ 2021
  • Fundamental
  • Price
  • LGVN $3.29
  • MYNZ $0.35
  • Analyst Decision
  • LGVN Strong Buy
  • MYNZ Buy
  • Analyst Count
  • LGVN 1
  • MYNZ 2
  • Target Price
  • LGVN $12.00
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • LGVN 11.1M
  • MYNZ 1.4M
  • Earning Date
  • LGVN 08-09-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • LGVN N/A
  • MYNZ N/A
  • EPS Growth
  • LGVN N/A
  • MYNZ N/A
  • EPS
  • LGVN N/A
  • MYNZ N/A
  • Revenue
  • LGVN $978,000.00
  • MYNZ $895,479.00
  • Revenue This Year
  • LGVN $137.24
  • MYNZ $67.40
  • Revenue Next Year
  • LGVN $50.77
  • MYNZ $191.13
  • P/E Ratio
  • LGVN N/A
  • MYNZ N/A
  • Revenue Growth
  • LGVN N/A
  • MYNZ 69.00
  • 52 Week Low
  • LGVN $0.77
  • MYNZ $0.32
  • 52 Week High
  • LGVN $35.60
  • MYNZ $4.71
  • Technical
  • Relative Strength Index (RSI)
  • LGVN 56.11
  • MYNZ 37.39
  • Support Level
  • LGVN $3.36
  • MYNZ $0.39
  • Resistance Level
  • LGVN $4.88
  • MYNZ $0.46
  • Average True Range (ATR)
  • LGVN 0.69
  • MYNZ 0.07
  • MACD
  • LGVN 0.06
  • MYNZ 0.01
  • Stochastic Oscillator
  • LGVN 37.04
  • MYNZ 13.88

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: